ArticleRheumatology (Oxford, England)2021
The COVID-19 Global Rheumatology Alliance: evaluating the rapid design and implementation of an international registry against best practice.
Article in Rheumatology (Oxford, England), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 39 citations in OpenAlex.
- Harmonization of Real-World Data for Vaccine-Preventable Infectious Diseases: Integration of SARS-CoV-2 Diagnostic and Serologic Data From Multiple Sources.Open forum infectious diseases · 2026Article
- Social media in advancing equity and collaboration in rheumatology: the CORDIALITY review.RMD open · 2025Review
- Characteristics associated with poor COVID-19 outcomes in people with psoriasis, psoriatic arthritis and axial spondyloarthritis: data from the COVID-19 PsoProtect and Global Rheumatology Alliance physician-reported registries.Annals of the rheumatic diseases · 2023Article
- Social Media Use Among Members of the Assessment of Spondyloarthritis International Society: Results of a Web-Based Survey.Journal of medical Internet research · 2023Article
- Social Media for Research Discourse, Dissemination, and Collaboration in Rheumatology.Rheumatology and immunology research · 2022Article
- COVID-19 outcomes among rheumatic disease patients in Kuwait: Data from the COVID-19 Global Rheumatology Alliance (C19-GRA) physician registry.International journal of rheumatic diseases · 2022Article
- COVID-19 in people with rheumatic diseases: risks, outcomes, treatment considerations.Nature reviews. Rheumatology · 2022Review
- Article
- The impact of COVID-19 on rheumatology training-results from the COVID-19 Global Rheumatology Alliance trainee survey.Rheumatology advances in practice · 2022Article
- The Pediatric COVID-19 Registry in Kuwait: Methodology and Results of Pilot Phase.Medical principles and practice : international journal of the Kuwait University, Health Science Centre · 2022Article
- Risk of Severe SARS-CoV-2 Infection in Patients with Autoimmune Rheumatic Diseases in Qatar: A Cohort Matched Study.Qatar medical journal · 2022Article
- Myasthenia gravis and COVID-19: A case series and comparison with literature.Acta neurologica Scandinavica · 2021Article
- Lupus Cohorts.Rheumatic diseases clinics of North America · 2021Review
- COVID-19 in immunocompromised populations: implications for prognosis and repurposing of immunotherapies.Journal for immunotherapy of cancer · 2021Review
- Global research collaboration in a pandemic-challenges and opportunities: the COVID-19 Global Rheumatology Alliance.Current opinion in rheumatology · 2021Review
- Novel coronavirus disease-2019 (COVID-19) in people with rheumatic disease: Epidemiology and outcomes.Best practice & research. Clinical rheumatology · 2021Review
- Association of Race and Ethnicity With COVID-19 Outcomes in Rheumatic Disease: Data From the COVID-19 Global Rheumatology Alliance Physician Registry.Arthritis & rheumatology (Hoboken, N.J.) · 2021Article
- Whom Should Be Saved? A Proposed Ethical Framework for Allocating Scarce Medical Resources to COVID-19 Patients Using Fuzzy Logic.Frontiers in medicine · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 11 institutions in 5 countries.
Funding
Abstract
objectivesAs the coronavirus disease 2019 pandemic developed there was a paucity of data relevant to people living with rheumatic disease. This led to the development of a global, online registry to meet these information needs. This manuscript provides a detailed description of the coronavirus disease 2019 Global Rheumatology Alliance registry development, governance structure, and data collection, and insights into new ways of rapidly establishing global research collaborations to meet urgent research needs.
methodsWe use previously published recommendations for best practices for registry implementation and describe the development of the Global Rheumatology Alliance registry in terms of these steps. We identify how and why these steps were adapted or modified. In Phase 1 of registry development, the purpose of the registry and key stakeholders were identified on online platforms, Twitter and Slack. Phase 2 consisted of protocol and data collection form development, team building and the implementation of governance and policies.
resultsAll key steps of the registry development best practices framework were met, though with the need for adaptation in some areas. Outputs of the registry, two months after initial conception, are also described.
conclusionThe Global Rheumatology Alliance registry will provide highly useful, timely data to inform clinical care and identify further research priorities for people with rheumatic disease with coronavirus disease 2019. The formation of an international team, easily able to function in online environments and resulting in rapid deployment of a registry is a model that can be adapted for other disease states and future global collaborations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.